



Can-Fite Biopharma (NYSE American: CANF) (TASE: CFBI)

July 22, 2020

Recent Price: \$2.44

Market Data

Fiscal Year	December
Industry	Biopharma
Market Cap	\$9.8M
ADRs Outstanding	4.0M
Float	2.6M
Avg. Volume (30-day)	2,231,849
As of July 22, 2020	

Financial Data

Revenue (ttm)	\$2.0M
Cash (mrq)	\$2.8M
Debt (mrq)	\$0.0M

<http://www.canfite.com/>

Company Overview

Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite's drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite's intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately \$18 million received to date. Piclidenoson received approval for COVID-19 clinical trial in Israel in April 2020 and is expected to file its IND in the US in the near-term.

Value Proposition

CANF has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company's four current clinical trial programs target a combined market opportunity estimated at more than \$80 billion, and a recent strategic agreement with Univo Pharmaceuticals provides additional upside from cannabinoid-based treatments targeting the same A3AR receptor. CANF has secured multiple corporate partnerships and out-licensing deals and has received an estimated \$18 million to date in upfront and milestone payments. Multiple near-term milestones expected in second half 2019.

Investment Highlights

- **Advanced clinical stage drug development company with a compelling platform technology**
 - CANF's lead compound, CF101, is an oral drug that has been successfully tested in animal models and is currently in advanced stages of clinical development for Rheumatoid Arthritis (RA) and Psoriasis
 - CF102 is an oral drug currently being developed for the treatment of hepatocellular carcinoma (Primary Liver Cancer)
 - CF602 is a next generation compound with robust anti-inflammatory effects proven in a variety of autoimmune inflammatory and inflammatory animal models, and will be developed as a second-generation anti-inflammatory drug
 - Open-label, 2-arm study of Piclidenoson in COVID-19 patients began in April 2020; plan to file IND with US FDA near-term
- **Small molecule drug products in Phase II and Phase III clinical studies; covered by 13 patent families issued and pending**
 - Positive NAFLD / NASH Phase II final data reported in June 2020; \$35B opportunity
 - Liver Cancer Phase III trial design completed in June 2020; \$1.4B opportunity
 - Rheumatoid Arthritis Phase III trial ongoing; \$35B opportunity
 - Psoriasis Phase III trial ongoing; \$11.4B opportunity
- **Developing cannabinoid-based treatments for cancer, inflammatory, autoimmune, and metabolic diseases**
 - Collaborating on development through strategic partnership with Univo Pharmaceuticals
 - Developing assays for other pharma companies; additional potential revenue driver
- **Highly experienced management, clinical, and regulatory team**
- **Successful corporate partnerships and licensing deals**
 - Approximately \$18 million upfront and milestone payments received to date

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a monthly cash fee of \$5,000 per month for 12 months of RedChip investor awareness services and consulting services. RedChip Companies also owns 16,500 shares of CANF Rule 144 stock, acquired in August 2019. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.